Clinical Trial Update: HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the HDAC inhibitor vorinostat (SAHA) in combination with capecitabine (Xeloda) using a new weekly dosing regimen in patients with adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Xeloda (capecitabine)
• Zolinza (vorinostat)

Snippet

Sponsor: Yale University | Conditions: Advanced Breast Cancer | Phase 1 | Status: COMPLETED